Clinical and echocardiographic features associated with improved survival in patients with severe aortic stenosis undergoing balloon aortic valvuloplasty (BAV)

Mustafa Husaini, Yuko Soyama, Nobuyuki Kagiyama, Prashanth Thakker, Manoj Thangam, Nowrin Haque, Elena Deych, Marc Sintek, John Lasala, John Gorcsan, Alan Zajarias

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background. Balloon aortic valvuloplasty (BAV) is used in high-risk patients with severe aortic stenosis (AS) when the benefit of transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) is unclear. Our objective was to identify clinical or echocardiographic features that identify patients likely to benefit from BAV. Methods. We studied 141 consecutive patients who underwent BAV from July, 2011 to October, 2017. Clinical characteristics, routine echocardiographic parameters, and speckle tracking imaging of global longitudinal strain (GLS) were assessed before and after BAV. The primary outcome was all-cause mortality as ascertained by the National Death Index. Results. There were 141 patients, median age, 80 years (interquartile range [IQR], 74-87 years) with severe AS (median aortic valve area, 0.66 cm2; IQR, 0.53-0.79 cm2) and median mean gradient of 36 mm Hg (IQR, 27-48 mm Hg) who underwent BAV. The 1-year mortality rate was 52%. Characteristics associated with survival were New York Heart Association class I symptoms, lower brain natriuretic peptide level, higher left ventricular ejection fraction (LVEF) >53%, and higher GLS (>13.2%; absolute values were used for GLS). Landmark analysis at 60 days showed the 47 patients who underwent TAVR/SAVR after BAV had significantly better 1-year survival than those who did not (P<.001). Conclusion. A high 1-year mortality rate was observed in severe AS patients selected for BAV. LVEF and left ventricular (LV)-GLS offer similar prognostic value for 1-year mortality; however, LV-GLS may have potentially increased clinical utility, as it provides a clear threshold for predicting poor outcomes compared with LVEF. As patients who undergo TAVR/SAVR have markedly improved mortality, careful consideration should be given to advance definitive valve therapy in carefully selected BAV patients.

Original languageEnglish (US)
Pages (from-to)277-285
Number of pages9
JournalJournal of Invasive Cardiology
Volume32
Issue number11
StatePublished - Nov 2020

All Science Journal Classification (ASJC) codes

  • General Medicine

Cite this